The deals keep rolling in, with Lilly penning a $7 billion pact for gene delivery biotech Kelonia Therapeutics and UCB taking ...

The newly approved HIV drug Idvynso will also help Merck diversify as loss of exclusivity looms over its top-selling product, ...

Finding the right people for critical open roles can be difficult even for biopharma leaders. In this column, Kaye/Bassman’s ...

With an IPO raise of $625 million, Kailera Therapeutics now holds the new record for the largest public market debut.

As technology becomes more integrated and personalized, experts say the biggest opportunity in diabetes management is ...

After receiving the FDA’s greenlight for Hunter syndrome drug Avlayah, Denali Therapeutics CEO Ryan Watts saw the culmination ...

While prominent physicians can provide companies with valuable guidance during development, their perspective is limited when ...

Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses ...

A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal ...

Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that ...

Replimune is axing 144 employees at its Woburn headquarters and 80 at its Framingham manufacturing site. The cuts follow the ...

With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily ...